drugset / Trial / NCT03602911

A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

NCT03602911

Phase 2 Completed 20 enrolled West Virginia University
NaSingle-groupOpen-labelDiagnostic

Summary

This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.

Timeline

Start
2019-02-01
Primary completion
2021-04-01
Completion
2021-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent
Subject 68Ga-DOTATOC Peptide